Cargando…

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several SARS-CoV-2 targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yun, Zhang, Qi, Cheng, Lin, Ge, Jiwan, Wang, Ruoke, Fang, Mengqi, Mucker, Eric M., Chen, Peng, Ma, Ji, Zhang, Rui, Li, Chunming, Hammond, Holly, Baracco, Lauren, Holbrook, Michael, Frieman, Matthew, Zhang, Zheng, Wang, Xinquan, Hooper, Jay W., Zhang, Linqi, Zhu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518701/
https://www.ncbi.nlm.nih.gov/pubmed/36189212
http://dx.doi.org/10.3389/fimmu.2022.980435
_version_ 1784799246448328704
author Ji, Yun
Zhang, Qi
Cheng, Lin
Ge, Jiwan
Wang, Ruoke
Fang, Mengqi
Mucker, Eric M.
Chen, Peng
Ma, Ji
Zhang, Rui
Li, Chunming
Hammond, Holly
Baracco, Lauren
Holbrook, Michael
Frieman, Matthew
Zhang, Zheng
Wang, Xinquan
Hooper, Jay W.
Zhang, Linqi
Zhu, Qing
author_facet Ji, Yun
Zhang, Qi
Cheng, Lin
Ge, Jiwan
Wang, Ruoke
Fang, Mengqi
Mucker, Eric M.
Chen, Peng
Ma, Ji
Zhang, Rui
Li, Chunming
Hammond, Holly
Baracco, Lauren
Holbrook, Michael
Frieman, Matthew
Zhang, Zheng
Wang, Xinquan
Hooper, Jay W.
Zhang, Linqi
Zhu, Qing
author_sort Ji, Yun
collection PubMed
description Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several SARS-CoV-2 targeting mAb by regulatory authority. However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. A YTE modification was introduced to the fragment crystallizable (Fc) region of both mAbs to prolong serum half-life and reduce effector function. The amubarvimab and romlusevimab combination retained activity against most mutations associated with reduced susceptibility to previously authorized mAbs and against variants containing amino acid substitutions in their epitope regions. Consistently, the combination of amubarvimab and romlusevimab effectively neutralized a wide range of viruses including most variants of concern and interest in vitro. In a Syrian golden hamster model of SARS-CoV-2 infection, animals receiving combination of amubarvimab and romlusevimab either pre- or post-infection demonstrated less weight loss, significantly decreased viral load in the lungs, and reduced lung pathology compared to controls. These preclinical findings support their development as an antibody cocktail therapeutic option against COVID-19 in the clinic.
format Online
Article
Text
id pubmed-9518701
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95187012022-09-29 Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2 Ji, Yun Zhang, Qi Cheng, Lin Ge, Jiwan Wang, Ruoke Fang, Mengqi Mucker, Eric M. Chen, Peng Ma, Ji Zhang, Rui Li, Chunming Hammond, Holly Baracco, Lauren Holbrook, Michael Frieman, Matthew Zhang, Zheng Wang, Xinquan Hooper, Jay W. Zhang, Linqi Zhu, Qing Front Immunol Immunology Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several SARS-CoV-2 targeting mAb by regulatory authority. However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. A YTE modification was introduced to the fragment crystallizable (Fc) region of both mAbs to prolong serum half-life and reduce effector function. The amubarvimab and romlusevimab combination retained activity against most mutations associated with reduced susceptibility to previously authorized mAbs and against variants containing amino acid substitutions in their epitope regions. Consistently, the combination of amubarvimab and romlusevimab effectively neutralized a wide range of viruses including most variants of concern and interest in vitro. In a Syrian golden hamster model of SARS-CoV-2 infection, animals receiving combination of amubarvimab and romlusevimab either pre- or post-infection demonstrated less weight loss, significantly decreased viral load in the lungs, and reduced lung pathology compared to controls. These preclinical findings support their development as an antibody cocktail therapeutic option against COVID-19 in the clinic. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9518701/ /pubmed/36189212 http://dx.doi.org/10.3389/fimmu.2022.980435 Text en Copyright © 2022 Ji, Zhang, Cheng, Ge, Wang, Fang, Mucker, Chen, Ma, Zhang, Li, Hammond, Baracco, Holbrook, Frieman, Zhang, Wang, Hooper, Zhang and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ji, Yun
Zhang, Qi
Cheng, Lin
Ge, Jiwan
Wang, Ruoke
Fang, Mengqi
Mucker, Eric M.
Chen, Peng
Ma, Ji
Zhang, Rui
Li, Chunming
Hammond, Holly
Baracco, Lauren
Holbrook, Michael
Frieman, Matthew
Zhang, Zheng
Wang, Xinquan
Hooper, Jay W.
Zhang, Linqi
Zhu, Qing
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title_full Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title_fullStr Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title_full_unstemmed Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title_short Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
title_sort preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against sars-cov-2
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518701/
https://www.ncbi.nlm.nih.gov/pubmed/36189212
http://dx.doi.org/10.3389/fimmu.2022.980435
work_keys_str_mv AT jiyun preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT zhangqi preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT chenglin preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT gejiwan preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT wangruoke preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT fangmengqi preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT muckerericm preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT chenpeng preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT maji preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT zhangrui preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT lichunming preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT hammondholly preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT baraccolauren preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT holbrookmichael preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT friemanmatthew preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT zhangzheng preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT wangxinquan preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT hooperjayw preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT zhanglinqi preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2
AT zhuqing preclinicalcharacterizationofamubarvimabandromlusevimabapairofnoncompetingneutralizingmonoclonalantibodycocktailagainstsarscov2